GxP work-orchestration OS that routes submission work across CROs and AI agents without breaking audit trails or data boundaries.

1. External labor is already too large and fragmented for regulated teams to keep managing it through disconnected back-office tools.
2. Buyers increasingly see contractors and AI agents as the same governance problem, which allows one budget owner to justify a unified control layer.
3. Compliance, sovereign data control, and certification work have become the gating spend before AI-assisted external work can scale.
4. Fortune 500 pilots in pharmaceuticals show the category has moved from concept to active enterprise evaluation.
5. Integration sprawl across VMS, HRIS, ERP, ATS, and orchestration tools creates demand for an overlay rather than another point solution.

Catalyst. Sherpa’s signal shows enterprises are already unifying contractor governance and AI-agent oversight, and spending on compliance and integrations to do it, creating an opening to own the regulated work packet now.

The product creates a GxP work packet for each submission deliverable and pulls approved CRO staff, freelancers, and bounded AI agents into one queue. It binds every task to approved source documents, templates, and SOPs, then records lineage, review, and payment events in a single audit trail. Integrations with RIM or eTMF systems, VMS tools, ERP or AP systems, and identity controls let customers keep existing systems of record while adding policy and evidence above them. AI agents can only operate inside scoped tasks with private deployment and reviewer checkpoints, so quality and sovereignty teams can approve narrow use cases before broader autonomy. The first measurable win is faster post-approval submission cycles with fewer handoff errors and cleaner audit packages.

What's different. Incumbent VMS tools manage vendors, and AI-governance tools manage model risk, but neither owns the regulated work packet where external humans and agents actually collaborate. This company starts at the submission artifact, not the worker or model, so it can unify assignment, policy, review evidence, and payment in one record. That artifact-native position is hard to replicate without deep workflow integrations and a growing corpus of audit-grade execution data.

Jobs to be done

flowchart LR
  Buyer[Regulatory Ops] --> Pain[Fragmented CRO and AI submission work]
  Pain --> Product[GxP work packet control plane]
  Product --> Outcome[Faster filings with audit-grade evidence]

Executive takeaways

• The wedge is real because pharma submission work already spans CROs, publishers, labeling vendors, and emerging AI augmentation, while incumbent tools split RIM, publishing, vendor governance, and compliance evidence [11][24][25][54][57].
• The product should position as an audit-grade control plane above RIM and service stacks rather than as a rip-and-replace suite; buyers already have systems of record, but not a single work-packet ledger [12][14][25][54][75][78].
• eCTD 4.0, revised EMA variation rules, and persistent data-integrity expectations are pushing teams from document handling toward metadata discipline, traceability, and governed automation [20][49][72][76][78][79][80].
• Commercial viability at six-figure ACV is believable because enterprises already fund adjacent external-workforce and workflow-control platforms with measurable ROI and large installed bases [10][22][54][88][92].

Market definition

The relevant market is software that governs regulated external-work packets for submission and labeling operations—sitting between RIM suites, CRO services, and workforce/VMS layers rather than replacing any of them [12][24][45][54].

Customer and buyer

The day-to-day operator is a head of regulatory operations or submission operations leader coordinating CRO authors, publishers, labeling vendors, and now AI-assisted document tasks. The economic buyer is usually VP Regulatory Operations, a RIM platform owner, or a QA-backed digital-regulatory sponsor because submission throughput, data integrity, and outsourced delivery all converge in that budget [25][28][54][60][94][96].

Buying triggers

• An AI drafting, review, or regulatory-intelligence pilot needs human oversight, traceability, and governed source-data boundaries before QA or regulatory leadership will scale it. [18][34][83][85][86]
• A submission delay, health-authority query, or post-authorisation change wave exposes fragmented data and manual vendor handoffs. [57][75][76][77]
• An audit, warning-letter scare, or internal data-integrity review surfaces weak evidence collection and inconsistent control of external contributors. [71][74][78][79]

Willingness to pay

Willingness to pay is credible because buyers already spend on adjacent control layers that save money or protect compliance. Beeline cites payback in under three months and 158% three-year ROI, Veeva shows 450+ RIM customers and 85+ organizations on continuous publishing, Parexel staffs 1,300+ regulatory specialists, and adjacent workforce/workflow software markets are already measured in billions. [10][22][54][88][90][92]

Category dynamics

Growth signal 10.1% CAGR

Validation signals

• Sherpa’s funding plus Fortune 500 pilot activity shows enterprises are already evaluating unified governance for human and AI external work.
• Veeva’s 450+ RIM customers and 85+ continuous-publishing users show the regulatory-operations buyer already funds workflow modernization at scale.
• Beeline’s Forrester study shows external-workforce governance platforms can generate fast, CFO-legible payback.
• RAPS and Syneos both frame regulatory operations as a talent and operating-model problem, which increases receptivity to orchestration and automation.

Regulatory & technical constraints

• Electronic records, signatures, and audit trails must be exportable and inspection-ready for regulated workflows.
• eCTD 4.0 introduces metadata, keyword, and validation requirements that increase the cost of messy source data and manual publishing handoffs.
• Post-authorisation changes require correct variation classification, grouped changes, and accurate manufacturing-site handling.
• AI-assisted work must preserve human oversight, documentation, monitoring, and trustworthy-AI controls.
• Data privacy and sovereignty matter when AI agents or external vendors touch regulated documents and product information.

Competition is dense but fragmented. Veeva and Ennov own regulated data and publishing workflows, IQVIA and CROs sell capacity plus compliance expertise, Beeline owns external-worker governance, and Sherpa proves human-plus-AI orchestration buyers exist. None of them natively centers the GxP submission work packet that ties assignment, allowed sources, review evidence, and payment together [12][24][45][3][11][54].

Why incumbents do not win by default

• RIM and submission suites. Veeva, Ennov, and similar suites manage dossiers, metadata, and publishing well, but their center of gravity is the submission record—not cross-vendor execution, QA sign-off sequencing, or payment gating.
• Regulatory services and CRO outsourcing. IQVIA, Parexel, ICON, and peers solve capacity and expertise gaps, but they do not automatically give the sponsor a reusable control plane across many vendors and AI agents.
• Extended workforce and SOW management. Beeline-style platforms are strong at supplier onboarding, spend visibility, and services procurement, but they are not submission- or GxP-artifact-native.
• AI-enabled regulatory automation. AI copilots can compress search, summarization, and draft generation, but regulated adoption still depends on traceability, human oversight, data governance, and RIM context.

GxP Submission Work OS should sell a sponsor-owned control plane for post-approval variations, renewals, and labeling submissions that already rely on multiple CROs, specialist vendors, and early AI-assisted tasks. The urgent pain is not document authoring alone; it is the lack of one audit-grade record showing who worked on each packet, which approved sources were used, whether SOP checkpoints cleared, and when vendor payment can be released. The first customer is a top-20 pharma regulatory-operations COE running 10-100 EU and U.S. post-approval packets a year, using 5-20 preferred CROs, and trying to scale an AI drafting or QC pilot without tripping QA or data-sovereignty concerns. The company should land as an overlay above RIM, publishing, and AP systems rather than trying to replace them, because buyers already fund those systems but still lack cross-vendor execution control. Research supports an estimated $30.0M beachhead SAM and roughly $6.0M year-3 SOM from 10 production logos at about $600k ARR, which is sufficient for a focused pre-seed wedge but only venture-attractive if the company later expands into labeling, pharmacovigilance, quality remediation, and broader regulated external-work orchestration. Go-to-market only works if the buying trigger, pilot scope, pricing basis, and distribution channel stay aligned: sell during an AI governance push, submission delay, or audit scare; start with one recurring post-approval workflow; price by active regulated work packets with a six-figure annual minimum; and use CRO and RIM implementation partners to reduce deployment risk. The biggest disconfirming risk is that sponsors continue to bundle the problem into CRO services or incremental RIM workflow instead of funding a new sponsor-owned control layer. Public evidence is still thin on which executive definitively owns budget among regulatory operations, RIM, QA, and procurement, so the first three pilots must prove both budget authority and sub-90-day deployment repeatability.

Problem

• Submission-operations teams spread one post-approval packet across CRO writers, publishers, labeling vendors, QA reviewers, spreadsheets, email, RIM tasks, and AP approvals, so no one system shows complete actor, source, review, and payment lineage.
• AI drafting or QC pilots intensify the control problem because QA and sovereignty teams need bounded source access, human checkpoints, and exportable evidence before they approve scale.

Solution

• Create a GxP work packet for each submission deliverable that binds approved humans and AI agents to allowed source documents, SOP steps, deadlines, and named reviewers.
• Overlay existing RIM, identity, and finance systems with immutable lineage, QA-ready audit exports, and payment-release controls so sponsors can speed recurring submissions without replacing core systems.

Why we win

• Incumbent RIM suites own dossier data, CROs own capacity, and VMS or procurement tools own supplier administration, but none natively centers the sponsor-owned submission work packet that connects execution, evidence, and payment.
• Starting with recurring post-approval packets creates reusable SOP templates, connector patterns, and exception history that reduce deployment time and build switching costs before broader regulated-work expansion.

Milestones

flowchart LR
  Wedge[Post-approval submission wedge] --> MVP[Work-packet control plane]
  MVP --> Proof[Cycle-time and audit-evidence gains]
  Proof --> Expansion[Labeling and broader regulated work]

Founding team

Experiment roadmap

Risk assessment

What must be true

• At least 40% of qualified top-50 pharma accounts already coordinate 5+ external contributors or agents outside a single auditable submission workflow.
• AI-regulatory pilots are blocked more by governance, lineage, and reviewer control than by model quality alone.
• One RIM integration plus export-based finance handoff is enough to launch the first governed packet inside 90 days.
• Paid pilot-to-production conversion stays above 50% when the product cuts request-to-QA cycle time by at least 20% or audit-package prep time by at least 50%.
• RIM suites, CROs, and procurement platforms remain unable or unwilling to combine source controls, QA evidence, and payment release in one sponsor-owned record.

Open diligence questions

• Which executive actually owns budget and policy authority for this wedge: VP Regulatory Operations, RIM, QA, or procurement?
• Which single integration is mandatory for the first pilot: RIM, identity, document repository, or ERP and AP?
• How often do post-approval packets create rework or audit-evidence scrambles because work crosses multiple vendors?
• Will CROs accept sponsor-owned task and payment gating, or do they resist the data-sharing model?
• Can the same control plane expand into labeling and pharmacovigilance without triggering a new implementation model each time?

Model sanity

• Revenue engine. Base-case revenue is driven by converting two Y1 paid pilots into 10 production logos by Q4Y3, with realized contract value stepping toward roughly $600K ARR per logo.
• Must go right. The company has to turn the first two pilots into referenceable production logos quickly enough that partners start feeding qualified opportunities before a large direct-sales team is hired.
• Model breaks if. If deployments stay above 90 days and buyers cap annual scope near $500K, the downside case pushes cash below zero even before Y3 finishes.
• Next-round proof. A seed round is justified once six production logos are live, deployment is repeatably under 90 days, and partner-sourced pipeline proves this is more than founder-led selling.

Scenarios

Sensitivity

flowchart LR
  Discovery[Qualified discovery] --> Pilot[Paid pilot]
  Partners[CRO and RIM partners] --> Pilot
  Pilot --> Production[Production workflow]
  Production --> Expansion[More packet types and volume]
  Production --> Revenue[Subscription and implementation revenue]
  Expansion --> Revenue
  Revenue --> GrossProfit[Gross profit]
  GrossProfit --> Cash[Cash after opex]

Flags: The model assumes the first paid pilot starts by M7; a slower procurement cycle would push cash performance quickly toward the downside case. · Gross margin does not fully clear the BP 70% target until late Y3, so repeated bespoke validation or connector work would compress both EBITDA and runway. · The base case already reaches the researched 10-logo Y3 SOM anchor, so the long-term venture case still depends on expansion into labeling, pharmacovigilance, or other regulated workflows after the wedge works. · Revenue concentration stays high through Y3 because a small number of top-pharma logos drives most ARR and referenceability.

• Validation friction. Quality and regulatory teams may refuse AI-assisted work unless the product proves GxP validation, reviewer control, and exportable evidence from day one. Mitigation: Start by governing human-vendor workflows first, keep AI optional and tightly scoped, and ship audit-package exports that fit existing validation programs.
• Incumbent suite creep. RIM, VMS, or ERP vendors could add lightweight orchestration features and position them as good-enough extensions. Mitigation: Win on cross-system evidence, payment gating, and human-plus-agent policy controls that incumbents do not naturally own in one workflow record.
• Long enterprise sales cycles. Top pharma buyers move slowly and may require services-heavy deployments before standardizing on a new control layer. Mitigation: Sell into one post-approval workflow with a measurable cycle-time KPI, use implementation partners, and expand only after proving submission-speed and audit-value.